On October 25, 2011, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of quadrivalent human papillomavirus (HPV) vaccine in boys aged 11 or 12 years. The ACIP also recommended HPV vaccination for males aged 13 through 21 years, who have not initiated or completed the 3-dose series. Men aged 22 through 26 years may also be vaccinated. For men who have sex with men, as well as for immunocompromised males, including those with HIV infection, HPV vaccine is recommended through age 26 years if they did not get the vaccine when they were younger. These recently published recommendations replace the permissive guidance published in 2009, which stated that HPV vaccine may be given to males aged 9 through 26 years to prevent acquisition of genital warts.
The HPV vaccine is a strong weapon in cancer prevention. Quadrivalent HPV vaccine prevents infection with the HPV types that cause many anal, penile, and oropharyngeal cancers, as well as genital warts, in men. Each year in the United States, about 7000 cancers in men are caused by these HPV types. Clinical trials have shown the quadrivalent HPV vaccine to be very effective in preventing anal precancers and genital warts. The vaccine will likely prevent HPV-associated penile cancers, as well as oropharyngeal cancers, but no studies have yet demonstrated efficacy against these outcomes